Hematologic Malignancy
Chronic Lymphocytic Leukemia
CI-CAN-00002362BCLL · CLLExplore in graph →
Hematologic265 active trials6 approved drugs46 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002362BCLL · CLLExplore in graph →
Clinical trials
1,256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (239)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04657094 | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 4 | City of Hope Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 306 | Acerta Pharma BVINDUSTRY | 3 | May 5, 2026 |
| clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05618028 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | active not recruiting | Phase 1 | 78 | AbbVieINDUSTRY | 10 | May 4, 2026 | clinicaltrials |
| NCT03913949 | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | active not recruiting | Phase 1 | 74 | Ascentage Pharma Group Inc.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT05517265 | Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)(CICERO) | completed | — | 45 | iOMEDICO AGINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT06125795 | A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain(PROVIDENCE) | active not recruiting | — | 146 | AbbVieINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT06792994 | A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG(CLL2000) | recruiting | — | 2,000 | German CLL Study GroupOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT01500733 | PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 86 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03479268 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04028531 | Understanding Chronic Lymphocytic Leukemia | recruiting | — | 2,750 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04666038 | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN CLL-321) | active not recruiting | Phase 3 | 238 | Loxo Oncology, Inc.INDUSTRY | 24 | Apr 24, 2026 | clinicaltrials |
| NCT06205498 | Acalabrutinib Real World Italian obSErvational Study -ARISE(ARISE) | active not recruiting | — | 151 | AstraZenecaINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06839053 | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | recruiting | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02553447 | Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency | completed | N/A | 197 | University of NebraskaOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | active not recruiting | Phase 1 | 150 | Nkarta, Inc.INDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT02514083 | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | active not recruiting | Phase 2 | 29 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01890486 | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04560322 | Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | recruiting | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05183854 | Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial | recruiting | Phase 2 | 61 | University of UtahOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04488354 | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T | completed | Phase 1 | 16 | Calibr, a division of Scripps ResearchOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03085173 | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02518555 | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 42 | Jennifer WoyachOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03467867 | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | active not recruiting | Phase 2 | 25 | Georgetown UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05972577 | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | completed | N/A | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT01723839 | Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide(FCR) | completed | Phase 2 | 21 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06208735 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | recruiting | Phase 1 | 24 | British Columbia Cancer AgencyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT00931645 | Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia(Auto-LLC 2001) | completed | Phase 3 | 241 | University Hospital, CaenOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT01393366 | Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention Strategy(FORTIS) | completed | N/A | 60 | University Hospital, ToulouseOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07030400 | Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma | recruiting | — | 100 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06536452 | Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects | recruiting | — | 50 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05147467 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 2 | 75 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05702853 | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | recruiting | Phase 1 / Phase 2 | 27 | Medical University of South CarolinaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02717611 | A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | active not recruiting | Phase 2 | 60 | Acerta Pharma BVINDUSTRY | 6 | Mar 25, 2026 | clinicaltrials |
| NCT05388006 | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 2 | 27 | Mayo ClinicOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03534323 | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS | active not recruiting | Phase 1 / Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06211413 | Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors(SENTINEL) | enrolling by invitation | — | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07487428 | CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL(CLL-IMPACT) | recruiting | N/A | 50 | Technical University of MunichOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 248 | Nurix Therapeutics, Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04629729 | FT819 in Subjects With B-cell Malignancies | active not recruiting | Phase 1 | 54 | Fate TherapeuticsINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT04904588 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide(ACCESS) | active not recruiting | Phase 2 | 300 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02135133 | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | terminated | Phase 1 | 84 | MEI Pharma, Inc.INDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05478512 | Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL(VIS) | active not recruiting | Phase 2 | 78 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation(ACCELERATE) | recruiting | Phase 2 | 358 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05624554 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | active not recruiting | Phase 3 | 300 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 16, 2026 | clinicaltrials |
| NCT07474051 | Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials(PERSIST) | enrolling by invitation | — | 178 | AvenCell Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 6, 2026source: clinicaltrials